This is a Study to Determine the Antidepressant Effects of AZD6765

Treatment Resistant Major Depressive Disorder Clinical Trial

Official title:
An Investigation of the Antidepressant Effects of an NMDA Antagonist in Treatment-Resistant Major Depression

Status Completed

Clinical Trial Summary

The purpose of this study is to determine the antidepressant effects of AZD6765 compared to placebo.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Depression
Depressive Disorder
Depressive Disorder, Major
Treatment Resistant Major Depressive Disorder

Clinical Trial Details

NCT number	NCT00986479
Study type	Interventional
Source	AstraZeneca
Contact
Status	Completed
Phase	Phase 2
Start date	December 2009
Completion date	December 2011

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT05323019` - Repeated Intranasal Esketamine Plus Almond Therapy in Patients With Treatment Resistant Depression	Phase 2
Completed	`NCT02977299` - Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD	Phase 4
Completed	`NCT02741791` - A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder	Phase 3
Terminated	`NCT03254017` - Remotely Programmed Deep Brain Stimulation of the Bilateral Habenula for Treatment- Resistant Major Depression: An Open Label Pilot Trial	N/A
Withdrawn	`NCT05438758` - Repeated Intranasal Esketamine Plus Almond Therapy in Participants With Treatment Resistant Depressive Disorder - 3 Month Extension Study	Phase 2
Active, not recruiting	`NCT01798407` - DBS of the Lateral Habenula in Treatment-Resistant Depression	N/A